What We're Reading: Page 90
Industry reads hand-picked by our editors
Apr 27, 2023
Apr 26, 2023
-
The Wall Street Journal
Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut
-
Reuters
EU publishes proposed drug laws overhaul, setting up tussle with industry
-
Evaluate Vantage
GSK says more deals to come as oncology takes another blow
-
C&EN
Drug services providers gird for an oligonucleotide surge
Apr 25, 2023
-
The Wall Street Journal
Weight-Loss Drugmakers Lobby for Medicare Coverage
-
Axios
Lyme disease vaccine could be coming soon
-
MarketWatch
Assertio to Acquire Outstanding Shares of Spectrum Pharmaceuticals
Apr 24, 2023
-
The Wall Street Journal
J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market
-
Reuters
‘It totally backfired’: The pitfalls of Alzheimer’s genetic testing
-
KFF Health News
Pain, Hope, and Science Collide as Athletes Turn to Magic Mushrooms
-
Healthcare Dive
‘Hurtling into the future’: The potential and thorny ethics of generative AI in healthcare
Apr 21, 2023
-
Reuters
Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
-
Financial Times
Activist investor ramps up pressure on incoming Bayer boss
-
Axios
Drug pricing rules set up potential challenge from pharmaceutical industry
-
Bloomberg
Virus Hunters Search for Diseases Supercharged by Climate Change
Apr 20, 2023
Apr 19, 2023
-
Bloomberg
Big Drugmakers Like Merck Are Forced to Pay Up in M&A for R&D Neglect
-
The Wall Street Journal
Unexpected Ozempic Side Effect? Weird Dreams
-
C&EN
Generative AI is dreaming up new proteins
Previous
